Leukemia Research
Volume 29, Issue 7 , Pages 771-783, July 2005

Establishment and characterization of SRIK-NKL: a novel CD8+ natural killer/T cell line derived from a patient with leukemic phase of acute lymphoblastic lymphoma

  • Bejai I.S. Srivastava

      Affiliations

    • Department of Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    • ,
  • Maya D. Srivastava

      Affiliations

    • The Division of Allergy and Immunology, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 216 444 6945; fax: +1 216 445 2104; pager: +1 800 329 3709.

Received 11 July 2004; accepted 17 December 2004. published online 07 March 2011.

Abstract 

The distinction between T cells and NK cells is difficult, and becoming more complex, as the diversity of the human lymphocyte repertoire is evident. We report the establishment of a permanent CD8+ NK/T cell line (SRIK-NKL) from a patient with leukemic phase of acute lymphoblastic lymphoma having characteristics of both NK and T cells, and extensively describe its phenotype, including cytotoxic activity, NK cell receptor expression, and other molecules critical for immune function. We further compare SRIK-NKL to other available NK/NK-T cell lines. SRIK-NKL may be useful for studying NK cell development, functions, and modulation, leading to novel strategies for treatment of autoimmune disease, infection, and cancer.

Keywords: Natural killer cell, Leukemia, Receptor, Cytotoxicity, CD8, Cytokine, Adhesion, Translocation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0145-2126(05)00030-5

doi:10.1016/j.leukres.2004.12.017

Leukemia Research
Volume 29, Issue 7 , Pages 771-783, July 2005

Article Tools

* Image Usage & Resolution